Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Jun-23 4:00 PM View:  | Stenhouse Mark Chief Operating Officer | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 12,754 | -- | -- | (48%) 26.75K to 14.0K | |
| 16-Jun-23 4:00 PM View: | Adams Helen C. Director | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 2,674 | -- | -- | (100%) 2.67K to 0 | |
| 16-Jun-23 4:00 PM View: | Papa Joseph C Director | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 10,000 | -- | -- | (100%) 10.0K to 0 | |
| 16-Jun-23 4:00 PM View: | Stenhouse Mark Chief Operating Officer | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 14,000 | -- | -- | (100%) 14.0K to 0 | |
| 16-Jun-23 4:00 PM View: | Szela Mary T Director | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 2,071 | -- | -- | (100%) 2.07K to 0 | |
| 16-Jun-23 4:00 PM View: | Laur James Director | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 2,071 | -- | -- | (100%) 2.07K to 0 | |
| 16-Jun-23 4:00 PM View: | McKenna Mark C. Chairman, President and CEO Director | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 178,098 | -- | -- | (100%) 178.1K to 0 | |
| 16-Jun-23 4:00 PM View: | Swain Judith L Director | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 2,071 | -- | -- | (100%) 2.07K to 0 | |
| 16-Jun-23 4:00 PM View: | Hendrix Martin Director | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 2,071 | -- | -- | (100%) 2.07K to 0 | |
| 16-Jun-23 4:00 PM View: | Papa Joseph C Director | Prometheus Biosciences, Inc. (RXDX) | 16-Jun-23 | Disposition | 7,278 | -- | -- | (42%) 17.28K to 10.0K | |
| 02-Jun-23 6:43 PM View: | Papa Joseph C Director | Prometheus Biosciences, Inc. (RXDX) | 02-Jun-23 | Disposition (other) | 10,000 | -- | -- | (37%) 27.28K to 17.28K | |
| 02-Jun-23 7:13 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 02-Jun-23 | Option Exercise | 122,531 | $2.90 | $355,336.00 | 221% 55.51K to 178.04K | |
| 02-Jun-23 6:43 PM View: | Papa Joseph C Director | Prometheus Biosciences, Inc. (RXDX) | 02-Jun-23 | Acquisition (other) | 10,000 | -- | -- | 58% 17.28K to 27.28K | |
| 02-Jun-23 7:03 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 02-Jun-23 | Option Exercise | 78,162 | $3.10 | $242,302.00 | 797% 9.81K to 87.97K | |
| 02-Jun-23 6:57 PM View: | Stenhouse Mark Chief Operating Officer | Prometheus Biosciences, Inc. (RXDX) | 01-Jun-23 | Disposition (other) | 14,000 | -- | -- | (34%) 40.71K to 26.71K | |
| 02-Jun-23 6:57 PM View: | Stenhouse Mark Chief Operating Officer | Prometheus Biosciences, Inc. (RXDX) | 01-Jun-23 | Acquisition (other) | 14,000 | -- | -- | 52% 26.71K to 40.71K | |
| 19-May-23 5:47 PM View: | Szela Mary T Director | Prometheus Biosciences, Inc. (RXDX) | 19-May-23 | Grant | 2,071 | -- | -- | 100% 0 to 2.07K | |
| 19-May-23 5:42 PM View: | Laur James Director | Prometheus Biosciences, Inc. (RXDX) | 19-May-23 | Grant | 2,071 | -- | -- | 100% 0 to 2.07K | |
| 19-May-23 5:45 PM View: | Swain Judith L Director | Prometheus Biosciences, Inc. (RXDX) | 19-May-23 | Grant | 2,071 | -- | -- | 100% 0 to 2.07K | |
| 19-May-23 5:41 PM View: | Hendrix Martin Director | Prometheus Biosciences, Inc. (RXDX) | 19-May-23 | Grant | 2,071 | -- | -- | 100% 0 to 2.07K | |
| 19-May-23 5:44 PM View: | Papa Joseph C Director | Prometheus Biosciences, Inc. (RXDX) | 19-May-23 | Grant | 2,278 | -- | -- | 15% 15.0K to 17.28K | |
| 19-May-23 5:38 PM View: | Adams Helen C. Director | Prometheus Biosciences, Inc. (RXDX) | 19-May-23 | Grant | 2,174 | -- | -- | 435% 0.5K to 2.67K | |
| 19-May-23 5:39 PM View: | Hassan Fred Director | Prometheus Biosciences, Inc. (RXDX) | 19-May-23 | Grant | 2,123 | -- | -- | 100% 0 to 2.12K | |
| 07-Apr-23 9:02 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 05-Apr-23 | Option Exercise | 10,000 | $3.70 | $37,000.00 | 102% 9.81K to 19.81K | |
| 07-Apr-23 9:02 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 05-Apr-23 | Planned Option Sale | 10,000 | $108.42 | $1,084,200.00 | (50%) 19.81K to 9.81K | |
| 17-Mar-23 9:02 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 15-Mar-23 | Planned Option Sale | 25,000 | $116.14 | $2,903,500.00 | (31%) 80.14K to 55.14K | |
| 17-Mar-23 9:02 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 15-Mar-23 | Option Exercise | 25,000 | $2.90 | $72,500.00 | 45% 55.14K to 80.14K | |
| 08-Mar-23 9:30 PM View: | Cedars Sinai Intellectual P... 10% Owner | Prometheus Biosciences, Inc. (RXDX) | 08-Mar-23 | Private Sale | 865,000 | $114.59 | $99,120,304.00 | (18%) 4.87M to 4.0M | |
| 08-Mar-23 9:33 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 06-Mar-23 | Planned Option Sale | 10,000 | $122.13 | $1,221,300.00 | (50%) 19.81K to 9.81K | |
| 08-Mar-23 9:33 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 06-Mar-23 | Option Exercise | 10,000 | $3.70 | $37,000.00 | 102% 9.81K to 19.81K | |
| 03-Mar-23 10:00 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 03-Mar-23 | Option Exercise | 10,620 | $3.70 | $39,294.00 | 19% 55.14K to 65.76K | |
| 03-Mar-23 10:00 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 03-Mar-23 | Planned Option Sale | 10,620 | $125.13 | $1,328,880.00 | (16%) 65.76K to 55.14K | |
| 03-Mar-23 10:00 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 01-Mar-23 | Planned Option Sale | 700 | $125.26 | $87,682.00 | (1%) 55.84K to 55.14K | |
| 03-Mar-23 10:00 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 01-Mar-23 | Option Exercise | 700 | $3.70 | $2,590.00 | 1% 55.14K to 55.84K | |
| 17-Feb-23 9:31 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 17-Feb-23 | Planned Option Sale | 13,680 | $125.10 | $1,711,370.00 | (20%) 68.82K to 55.14K | |
| 17-Feb-23 9:31 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 17-Feb-23 | Option Exercise | 13,680 | $3.70 | $50,616.00 | 25% 55.14K to 68.82K | |
| 17-Feb-23 9:31 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 16-Feb-23 | Option Exercise | 25,000 | $3.70 | $92,500.00 | 45% 55.14K to 80.14K | |
| 17-Feb-23 9:31 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 16-Feb-23 | Planned Option Sale | 25,000 | $119.87 | $2,996,750.00 | (31%) 80.14K to 55.14K | |
| 17-Feb-23 9:31 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 15-Feb-23 | Planned Option Sale | 25,000 | $119.42 | $2,985,500.00 | (31%) 80.14K to 55.14K | |
| 17-Feb-23 9:34 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 15-Feb-23 | Option Exercise | 5,000 | $3.70 | $18,500.00 | 51% 9.81K to 14.81K | |
| 17-Feb-23 9:34 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 15-Feb-23 | Planned Option Sale | 5,000 | $119.38 | $596,900.00 | (34%) 14.81K to 9.81K | |
| 17-Feb-23 9:31 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 15-Feb-23 | Option Exercise | 25,000 | $2.90 | $72,500.00 | 45% 55.14K to 80.14K | |
| 19-Jan-23 8:42 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 17-Jan-23 | Option Exercise | 5,000 | $3.70 | $18,500.00 | 51% 9.81K to 14.81K | |
| 19-Jan-23 8:42 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 17-Jan-23 | Planned Option Sale | 5,000 | $119.00 | $595,000.00 | (34%) 14.81K to 9.81K | |
| 19-Jan-23 8:39 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 17-Jan-23 | Option Exercise | 25,000 | $2.90 | $72,500.00 | 45% 55.14K to 80.14K | |
| 19-Jan-23 8:39 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 17-Jan-23 | Planned Option Sale | 25,000 | $118.99 | $2,974,750.00 | (31%) 80.14K to 55.14K | |
| 13-Dec-22 8:32 PM View: | McKenna Mark C. Chairman, President & CEO Director | Prometheus Biosciences, Inc. (RXDX) | 09-Dec-22 | Grant | 37,113 | -- | -- | 206% 18.03K to 55.14K | |
| 13-Dec-22 8:38 PM View: | Stenhouse Mark Chief Operating Officer | Prometheus Biosciences, Inc. (RXDX) | 09-Dec-22 | Grant | 9,811 | -- | -- | 59% 16.63K to 26.44K | |
| 13-Dec-22 8:35 PM View: | Marshall Keith W Chief Financial Officer | Prometheus Biosciences, Inc. (RXDX) | 09-Dec-22 | Grant | 9,811 | -- | -- | 100% 0 to 9.81K | |
| 05-Apr-22 5:49 PM View: | Cedars Sinai Intellectual P... 10% Owner | Prometheus Biosciences, Inc. (RXDX) | 05-Apr-22 | Disposition (other) | 142,376 | -- | -- | (3%) 5.01M to 4.87M |
